CA-CLICKHOUSE
30.7.2024 16:01:35 CEST | Business Wire | Press release
ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytical database, is thrilled to announce the acquisition of PeerDB, a leading provider of change data capture (CDC) solutions for Postgres databases. This strategic acquisition underscores ClickHouse’s commitment to delivering unparalleled real-time analytics and data integration capabilities to its customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730221289/en/
ClickHouse acquires PeerDB to boost real-time analytics with Postgres CDC integration (Graphic: Business Wire)
PeerDB’s technology significantly reduces the time it takes to connect data in transactional databases like Postgres with analytical databases like ClickHouse, boosting developer productivity and time-to-value when building real-time data driven applications. With PeerDB CDC technology integrated into ClickHouse Cloud, users will benefit from seamless, real-time data replication from Postgres databases to ClickHouse.
“We are excited to welcome PeerDB into ClickHouse,” said Aaron Katz, CEO of ClickHouse, Inc. “This acquisition aligns with our mission to empower our customers with the most advanced and efficient data analytics solutions. By integrating PeerDB’s CDC technology, we are empowering Postgres developers to move even faster when building real-time data driven applications. Now, all they have to do is configure a mirror between their existing Postgres databases and ClickHouse, and the data is available for lightning-fast analytical queries.”
Sai Krishna Srirampur, CEO of PeerDB, expressed his enthusiasm for what the future holds, stating, “We are thrilled to join forces with ClickHouse. This acquisition is a natural evolution for us at PeerDB, as we already share many joint enthusiastic users with ClickHouse. Postgres is becoming the de facto operational database, while ClickHouse is the fastest analytical database on the planet. Both originate from the same open-source ethos. This acquisition bridges the gap between Postgres and ClickHouse, enabling businesses to seamlessly move their operational data for real-time analytics.”
Javier Erro Garcia, Cloud Architecture Manager at Vueling Airlines, shared excitement about the upcoming integration: “As a user of both ClickHouse Cloud and PeerDB, I am thrilled about this acquisition. We already reduced our Postgres to ClickHouse snapshot times from 10+ hours down to 15 minutes with PeerDB. Combining ClickHouse’s powerful analytics natively with PeerDB’s real-time data capture capabilities will greatly simplify our data processing workflows. This integration will enable us to build analytical applications faster, giving us a competitive edge in the market.”
The combined expertise of ClickHouse and PeerDB will pave the way for the development of new features and capabilities aimed at meeting the evolving needs of data-driven enterprises. Customers can look forward to deeper integration between PeerDB Cloud and ClickHouse Cloud and support for additional CDC data sources. The ClickHouse technical blog post introducing the acquisition provides more detail.
About ClickHouse
ClickHouse is a fast, open-source, columnar OLAP database management system. It allows users to generate analytics using SQL queries in real-time. Designed to analyze large volumes of data, ClickHouse is used by industry leaders around the globe for its unmatched performance, scalability, and reliability.
About PeerDB
PeerDB is a leading provider of change data capture (CDC) solutions for Postgres databases. Their technology enables real-time data replication and synchronization, helping businesses keep their data up-to-date and accessible for analytics and decision-making processes.
PeerDB was founded by Kaushik Iska and Sai Srirampur in mid 2023 and has since grown to become a leading Postgres data replication company in the market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730221289/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom